Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

Cuiqing Ma, Ye Li, Lili Wang, Guangyu Zhao, Xinrong Tao, Chien-Te Tseng, Yusen Zhou, Lanying Du, Shibo Jiang

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle East and Europe, raising a serious concern about its pandemic potential. Therefore, development of effective vaccines is crucial for preventing its further spread and future pandemic. Our previous study has shown that subcutaneous (s.c.) vaccination of a recombinant protein containing receptor-binding domain (RBD) of MERS-CoV S fused with Fc of human IgG (RBD-Fc) induced strong systemic neutralizing antibody responses in vaccinated mice. Here, we compared local and systemic immune responses induced by RBD-Fc via intranasal (i.n.) and s.c. immunization pathways. We found that i.n. vaccination of MERS-CoV RBD-Fc induced systemic humoral immune responses comparable to those induced by s.c. vaccination, including neutralizing antibodies, but more robust systemic cellular immune responses and significantly higher local mucosal immune responses in mouse lungs. This study suggests the potential of developing MERS-CoV RBD protein into an effective and safe mucosal candidate vaccine for prevention of respiratory tract infections caused by MERS-CoV.

Original languageEnglish (US)
Pages (from-to)2100-2108
Number of pages9
JournalVaccine
Volume32
Issue number18
DOIs
StatePublished - Apr 11 2014

Fingerprint

Coronavirus Infections
mucosal immunity
Mucosal Immunity
Middle East
Immunization
immunization
Vaccination
Vaccines
vaccination
vaccines
receptors
Pandemics
Neutralizing Antibodies
Proteins
proteins
pandemic
neutralizing antibodies
IgG Receptors
Saudi Arabia
Humoral Immunity

Keywords

  • MERS-CoV
  • Mucosal immune response
  • Neutralizing antibody
  • Receptor-binding domain
  • Spike protein
  • Systemic immune response

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization : Implication for designing novel mucosal MERS vaccines. / Ma, Cuiqing; Li, Ye; Wang, Lili; Zhao, Guangyu; Tao, Xinrong; Tseng, Chien-Te; Zhou, Yusen; Du, Lanying; Jiang, Shibo.

In: Vaccine, Vol. 32, No. 18, 11.04.2014, p. 2100-2108.

Research output: Contribution to journalArticle

@article{e1ee0211fec8409ab76bbd0daa48a0a1,
title = "Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines",
abstract = "Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle East and Europe, raising a serious concern about its pandemic potential. Therefore, development of effective vaccines is crucial for preventing its further spread and future pandemic. Our previous study has shown that subcutaneous (s.c.) vaccination of a recombinant protein containing receptor-binding domain (RBD) of MERS-CoV S fused with Fc of human IgG (RBD-Fc) induced strong systemic neutralizing antibody responses in vaccinated mice. Here, we compared local and systemic immune responses induced by RBD-Fc via intranasal (i.n.) and s.c. immunization pathways. We found that i.n. vaccination of MERS-CoV RBD-Fc induced systemic humoral immune responses comparable to those induced by s.c. vaccination, including neutralizing antibodies, but more robust systemic cellular immune responses and significantly higher local mucosal immune responses in mouse lungs. This study suggests the potential of developing MERS-CoV RBD protein into an effective and safe mucosal candidate vaccine for prevention of respiratory tract infections caused by MERS-CoV.",
keywords = "MERS-CoV, Mucosal immune response, Neutralizing antibody, Receptor-binding domain, Spike protein, Systemic immune response",
author = "Cuiqing Ma and Ye Li and Lili Wang and Guangyu Zhao and Xinrong Tao and Chien-Te Tseng and Yusen Zhou and Lanying Du and Shibo Jiang",
year = "2014",
month = "4",
day = "11",
doi = "10.1016/j.vaccine.2014.02.004",
language = "English (US)",
volume = "32",
pages = "2100--2108",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "18",

}

TY - JOUR

T1 - Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization

T2 - Implication for designing novel mucosal MERS vaccines

AU - Ma, Cuiqing

AU - Li, Ye

AU - Wang, Lili

AU - Zhao, Guangyu

AU - Tao, Xinrong

AU - Tseng, Chien-Te

AU - Zhou, Yusen

AU - Du, Lanying

AU - Jiang, Shibo

PY - 2014/4/11

Y1 - 2014/4/11

N2 - Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle East and Europe, raising a serious concern about its pandemic potential. Therefore, development of effective vaccines is crucial for preventing its further spread and future pandemic. Our previous study has shown that subcutaneous (s.c.) vaccination of a recombinant protein containing receptor-binding domain (RBD) of MERS-CoV S fused with Fc of human IgG (RBD-Fc) induced strong systemic neutralizing antibody responses in vaccinated mice. Here, we compared local and systemic immune responses induced by RBD-Fc via intranasal (i.n.) and s.c. immunization pathways. We found that i.n. vaccination of MERS-CoV RBD-Fc induced systemic humoral immune responses comparable to those induced by s.c. vaccination, including neutralizing antibodies, but more robust systemic cellular immune responses and significantly higher local mucosal immune responses in mouse lungs. This study suggests the potential of developing MERS-CoV RBD protein into an effective and safe mucosal candidate vaccine for prevention of respiratory tract infections caused by MERS-CoV.

AB - Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle East and Europe, raising a serious concern about its pandemic potential. Therefore, development of effective vaccines is crucial for preventing its further spread and future pandemic. Our previous study has shown that subcutaneous (s.c.) vaccination of a recombinant protein containing receptor-binding domain (RBD) of MERS-CoV S fused with Fc of human IgG (RBD-Fc) induced strong systemic neutralizing antibody responses in vaccinated mice. Here, we compared local and systemic immune responses induced by RBD-Fc via intranasal (i.n.) and s.c. immunization pathways. We found that i.n. vaccination of MERS-CoV RBD-Fc induced systemic humoral immune responses comparable to those induced by s.c. vaccination, including neutralizing antibodies, but more robust systemic cellular immune responses and significantly higher local mucosal immune responses in mouse lungs. This study suggests the potential of developing MERS-CoV RBD protein into an effective and safe mucosal candidate vaccine for prevention of respiratory tract infections caused by MERS-CoV.

KW - MERS-CoV

KW - Mucosal immune response

KW - Neutralizing antibody

KW - Receptor-binding domain

KW - Spike protein

KW - Systemic immune response

UR - http://www.scopus.com/inward/record.url?scp=84896545485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896545485&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.02.004

DO - 10.1016/j.vaccine.2014.02.004

M3 - Article

C2 - 24560617

AN - SCOPUS:84896545485

VL - 32

SP - 2100

EP - 2108

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 18

ER -